Compare Kythera Biopharmaceuticals vs PhaseBio Pharmaceuticals
Customers evaluate the quality of Kythera Biopharmaceuticals's products using the following success metrics.
Overview
Kythera Biopharmaceuticals is 19 yrs old and is based in United States.
Kythera (NASDAQ: KYTH) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine.
PhaseBio Pharmaceuticals is 22 yrs old and is based in United States.
PhaseBio Pharmaceuticals (NASDAQ: PHAS) develops drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases. The Company's discovery platform technology uses recombinant ELP biopolymers to control the half-life, bioavailability, and physical characteristics of molecules for ease of administration. It was founded in 2002 and is based in Malvern, Pennsylvania.
Demo Video
Leadership
Jay E. Birnbaum (Founder)
Jonathan P Mow (Chief Executive Officer)
Funding
Investors
Allergan, Versant Ventures
Johnson & Johnson Innovation, New Enterprise Associates
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Kythera Biopharmaceuticals has not claimed their profile.
Work for Kythera Biopharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Kythera Biopharmaceuticals?
Claim your profile now.
Information not available because PhaseBio Pharmaceuticals has not claimed their profile.
Work for PhaseBio Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for PhaseBio Pharmaceuticals?
Claim your profile now.